D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $14.00 price objective on the stock. D. Boral Capital’s price objective indicates a potential upside of 280.43% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

NASDAQ:CLGN traded up $0.02 during mid-day trading on Wednesday, reaching $3.68. 13,840 shares of the company’s stock were exchanged, compared to its average volume of 6,623. CollPlant Biotechnologies has a one year low of $3.24 and a one year high of $6.75. The business’s fifty day simple moving average is $3.84 and its two-hundred day simple moving average is $4.29. The firm has a market capitalization of $42.14 million, a PE ratio of -2.39 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, November 27th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the prior year, the firm earned ($0.38) EPS. As a group, equities research analysts forecast that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Trading of CollPlant Biotechnologies

Several large investors have recently bought and sold shares of CLGN. Benjamin Edwards Inc. bought a new stake in shares of CollPlant Biotechnologies in the 3rd quarter valued at $112,000. AMH Equity Ltd lifted its stake in shares of CollPlant Biotechnologies by 17.4% in the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the period. Finally, Villere ST Denis J & Co. LLC grew its stake in CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the period. 21.69% of the stock is owned by institutional investors and hedge funds.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.